These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30973968)

  • 1. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease.
    Sundelin EIO; Gormsen LC; Heebøll S; Vendelbo MH; Jakobsen S; Munk OL; Feddersen S; Brøsen K; Hamilton-Dutoit SJ; Pedersen SB; Grønbaek H; Jessen N
    Br J Clin Pharmacol; 2019 Aug; 85(8):1761-1770. PubMed ID: 30973968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
    Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
    Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic variation and metformin response.
    Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A
    Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin is distributed to tumor tissue in breast cancer patients in vivo: A
    Sundelin EIO; Al-Suliman N; Vahl P; Vendelbo M; Munk OL; Jakobsen S; Pedersen SB; Frøkiær J; Gormsen LC; Jessen N
    Breast Cancer Res Treat; 2020 May; 181(1):107-113. PubMed ID: 32240455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
    J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
    Rouabhia S; Milic N; Abenavoli L
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):343-9. PubMed ID: 24580044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of metformin.
    Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
    Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).
    Doycheva I; Loomba R
    Adv Ther; 2014 Jan; 31(1):30-43. PubMed ID: 24385405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
    Zolk O
    Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver.
    García-Calzón S; Perfilyev A; Männistö V; de Mello VD; Nilsson E; Pihlajamäki J; Ling C
    Clin Epigenetics; 2017; 9():102. PubMed ID: 28947922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
    Iogna Prat L; Tsochatzis EA
    Hormones (Athens); 2018 Jun; 17(2):219-229. PubMed ID: 29858843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
    Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
    Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.